Literature DB >> 28369305

Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES.

Adeel A Butt1,2,3, Yanjie Ren1, Vincent Lo Re4, Tamar H Taddei5,6, David E Kaplan7.   

Abstract

BACKGROUND: Identifying hepatitis C virus (HCV)-positive persons at high risk of early complications can help prioritize treatment decisions. We conducted this study to compare Child-Turcotte-Pugh (CP), MELD, and FIB-4 scores for predicting clinical outcomes and to identify those at low risk of complications.
METHODS: Within electronically retrieved cohort of HCV-infected veterans, we identified HCV-positive persons and excluded those with human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), prevalent hepatic decompensation (HD), hepatocellular carcinoma (HCC), and those treated for HCV. We calculated incidence rates for HD, HCC, and all-cause mortality at 1, 3, and 5 years after HCV diagnosis. Using receiver operating characteristic (ROC) curves, we determined the optimal cut-off values for each score for these outcomes.
RESULTS: Among 21 116 persons evaluated, 89.7% were CP Class-A, 79.9% had MELD<9, and 43.4% had FIB-4<1.45. AUROC for HD at 1, 3, and 5 years was higher for FIB-4 (0.84-0.86) compared with MELD (0.70-0.76) (P < .001). AUROC for HCC at 1, 3, and 5 years was 0.81-0.82 for FIB-4 but 0.61-0.68 for CP and MELD scores. (P < .001) AUROC for all-cause mortality at 3 and 5 years was 0.65-0.68. The optimal cut-off scores to identify persons at low risk of complications were as follows: CP <5; MELD <8; FIB-4 <3 for HD and HCC, and <2 for all-cause mortality, below which <1.5% developed HD and HCC and ≤2.5% died at 3 years.
CONCLUSIONS: FIB-4 score is a better predictor of HD and HCC in HCV-positive persons. A score of <3 is associated with a low risk of HD and HCC 1 and 3 years after HCV diagnosis.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com

Entities:  

Keywords:  ERCHIVES; HCV; mortality; outcomes; treatment

Mesh:

Year:  2017        PMID: 28369305     DOI: 10.1093/cid/cix224

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

1.  Serum immunoglobulin A levels and non-alcoholic fatty liver disease.

Authors:  Evan Elias; Julia Uhanova; Qian Li; Manna Zhang; Gerald Minuk
Journal:  Can Liver J       Date:  2018-12-25

2.  Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study.

Authors:  Deirdre Sawinski; Kimberly A Forde; Vincent Lo Re; David S Goldberg; Jordana B Cohen; Jayme E Locke; Roy D Bloom; Colleen Brensinger; Joe Weldon; Justine Shults; Peter P Reese
Journal:  Am J Kidney Dis       Date:  2019-01-29       Impact factor: 8.860

3.  Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors.

Authors:  Patrizia Carrieri; Fabrice Carrat; Vincent Di Beo; Marc Bourlière; Tangui Barré; Victor De Ledinghen; Georges-Philippe Pageaux; Morgane Bureau; Carole Cagnot; Céline Dorival; Elisabeth Delarocque-Astagneau; Fabienne Marcellin; Stanislas Pol; Hélène Fontaine; Camelia Protopopescu
Journal:  JHEP Rep       Date:  2022-03-30

4.  Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC.

Authors:  Ze-Qun Zhang; Li Xiong; Jiang-Jiao Zhou; Xiong-Ying Miao; Qing-Long Li; Yu Wen; Heng Zou
Journal:  World J Surg Oncol       Date:  2018-10-16       Impact factor: 2.754

5.  Acute sporadic hepatitis E in the Zhejiang coastal area of China: a 14-year hospital-based surveillance study.

Authors:  Jun Tan; Yijuan Chen; Lin Wang; Ta-Chien Chan; Said Amer; Xiaobin Xu; Jian Cai; Wei Li; Xiaoqing Zheng; Mi Zhou; Shuwen Qin; Na Zhao; Ziping Miao; Shelan Liu
Journal:  Virol J       Date:  2019-02-04       Impact factor: 4.099

6.  Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.

Authors:  GianLuca Colussi; Debora Donnini; Rosario Francesco Brizzi; Silvia Maier; Luca Valenti; Cristiana Catena; Alessandro Cavarape; Leonardo Alberto Sechi; Giorgio Soardo
Journal:  World J Gastroenterol       Date:  2019-10-28       Impact factor: 5.742

Review 7.  Non-invasive tests for the prediction of primary hepatocellular carcinoma.

Authors:  Giovanni Marasco; Antonio Colecchia; Giovanni Silva; Benedetta Rossini; Leonardo Henry Eusebi; Federico Ravaioli; Elton Dajti; Luigina Vanessa Alemanni; Luigi Colecchia; Matteo Renzulli; Rita Golfieri; Davide Festi
Journal:  World J Gastroenterol       Date:  2020-06-28       Impact factor: 5.742

8.  No Regional Disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 Infection in Tochigi Prefecture and Its Vicinity.

Authors:  Takuya Hirosawa; Naoki Morimoto; Kouichi Miura; Toshiyuki Tahara; Toshimitsu Murohisa; Yukishige Okamura; Takashi Sato; Norikatsu Numao; Masato Imai; Shigeo Tano; Kozue Murayama; Hidekazu Kurata; Iwao Ozawa; Yukimura Fukaya; Hiroaki Yoshizumi; Shunji Watanabe; Mamiko Tsukui; Yoshinari Takaoka; Hiroaki Nomoto; Norio Isoda; Hironori Yamamoto
Journal:  Intern Med       Date:  2018-10-17       Impact factor: 1.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.